Abstract: OBJECTIVE To evaluate the economic significance of capecitabine plus docetaxel versus epirubicin plus docetaxel for advanced or metastatic breast cancer. METHODS Based on Meta-analysis of the clinical efficacy of two regimes, selected the direct medical costs as the cost of each regime, established a decision tree with TreeAge Pro 2009 software, and made a cost-effectiveness analysis and sensitivity analysis. RESULTS After treatment cycles, the cost-effectiveness ratio of capecitabine plus docetaxel was higher than that of docetaxel and epirubicin. The stability of results was affected by fewer variables according to sensitivity analysis. CONCLUSION Two regimes are of similar efficacy, while cost of epirubicin plus docetaxel regime is of economic advantage.